TiumBio Co., Ltd. Logo

TiumBio Co., Ltd.

Biopharmaceutical firm developing therapeutics for rare and incurable diseases.

321550 | KO

Overview

Corporate Details

ISIN(s):
KR7321550006
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 창업로40번길 30 6층 (시흥동, 판교아이티센터), 성남시

Description

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-12 00:00
주식매수선택권부여에관한신고
Korean 17.0 KB
2025-03-12 00:00
주주총회집중일개최사유신고
Korean 4.9 KB
2025-03-12 00:00
주주총회소집공고
Korean 165.0 KB
2025-03-12 00:00
의결권대리행사권유참고서류
Korean 111.7 KB
2025-02-13 00:00
파생상품거래손실발생
Korean 5.9 KB
2025-02-12 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 12.2 KB
2025-01-21 00:00
기업설명회(IR)개최
Korean 7.0 KB
2024-12-27 00:00
합병등종료보고서(합병)
Korean 22.2 KB
2024-12-26 00:00
합병등종료보고서(자산양수도)
Korean 13.2 KB
2024-12-23 00:00
전환가액의조정
Korean 11.3 KB
2024-12-23 00:00
투자판단관련주요경영사항(임상시험결과) (혈우병 치료신약 TU7710의 임상 1a상 Topline 결과 발표)
Korean 18.3 KB
2024-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2024-12-04 00:00
기업설명회(IR)개최
Korean 7.0 KB
2024-12-02 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 12.2 KB
2024-11-22 00:00
[기재정정]주요사항보고서(회사합병결정)
Korean 111.4 KB

Automate Your Workflow. Get a real-time feed of all TiumBio Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TiumBio Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TiumBio Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.